Dr. Ernst Schweizer Appointed Head of Business Development at Genmab

23.01.2002

Copenhagen, Denmark - 21th January 2002 Genmab A/S (CSE: GEN and Neuer Markt: GE9D) today announced that Dr. Ernst Schweizer has been appointed Head of Business Development for the company.

Dr. Schweizer was most recently President of Medarex Europe and was previously the Deputy Director of Worldwide Business Development and Licensing for Novartis and Chief Scientific and Technical Adviser of Business Development and Licensing at Ciba-Geigy. He is a member of the Board of Directors at CoMab, Hyseq, Speedel and BioPharma Fund. Dr. Schweizer received his Ph.D. from the University of Stuttgart.

"Dr. Ernst Schweizer brings a wealth of industry experience and knowledge to Genmab and will be a valuable member of the senior management team," said Genmab's CEO Dr. Lisa N. Drakeman. "We look forward to him leading the business development team through what is for Genmab an exciting time of growth."

Weitere News aus dem Ressort

Meistgelesene News

Weitere News von unseren anderen Portalen

Kampf gegen Krebs: Neueste Entwicklungen und Fortschritte